 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...255256257258259260261262263264265266267» |
- Provenge (sipuleucel-T) / Bausch Health, Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Metastases: Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer (clinicaltrials.gov) - Mar 23, 2014
P1, N=9, Active, not recruiting, Sponsor: Prostate Oncology Specialists, Inc.
Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed: A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma (clinicaltrials.gov) - Mar 20, 2014
P1, N=18, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Yervoy (ipilimumab) / BMS
New P2 trial: Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma (clinicaltrials.gov) - Mar 19, 2014
P2, N=116, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change: Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (clinicaltrials.gov) - Mar 18, 2014
P1, N=175, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting N=72 --> 175
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Trial initiation date, PD(L)-1 Biomarker, Metastases: Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=12, Recruiting, Sponsor: Mayo Clinic
N=72 --> 175 Initiation date: Apr 2013 --> Mar 2014
- Yervoy (ipilimumab) / BMS
Enrollment open, Surgery: SRS (Stereotactic Radiosurgery) Plus Ipilimumab (clinicaltrials.gov) - Mar 17, 2014
P1, N=30, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Apr 2013 --> Mar 2014 Active, not recruiting --> Recruiting
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker, Metastases: Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=12, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Enrollment open: Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na (clinicaltrials.gov) - Mar 17, 2014
P1/2, N=25, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Metastases: KEYNOTE 029: Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) (clinicaltrials.gov) - Mar 16, 2014
P1/2, N=195, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy (clinicaltrials.gov) - Mar 13, 2014
P2, N=114, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Yervoy (ipilimumab) / BMS
Enrollment change: Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - Mar 11, 2014
P3, N=681, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting N=500 --> 681
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (clinicaltrials.gov) - Mar 11, 2014
P1/2, N=320, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=500 --> 681 Not yet recruiting --> Recruiting
- ||||||| Yervoy (ipilimumab) / BMS
Trial completion: Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - Mar 11, 2014
P3, N=681, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Keytruda (pembrolizumab) / Merck (MSD)
Metastases: Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) (clinicaltrials.gov) - Mar 9, 2014
P=N/A, N=0, Available, Sponsor: Merck Sharp & Dohme Corp.
- Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: GIPI: Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (clinicaltrials.gov) - Mar 5, 2014
P2, N=43, Active, not recruiting, Sponsor: Lynn E. Spitler, MD
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: E4412: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Mar 4, 2014
P1, N=27, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: Sep 2013 --> Jan 2014
- Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: E4412: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Mar 4, 2014
P1, N=27, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Sep 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma (clinicaltrials.gov) - Mar 3, 2014
P2, N=45, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Zelboraf (vemurafenib) / Roche, Yervoy (ipilimumab) / BMS
New P1 trial, Combination therapy: Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma (clinicaltrials.gov) - Mar 2, 2014
P1, N=20, Recruiting, Sponsor: Herlev Hospital
- ||||| indoximod (NLG8189) / Lumos Pharma
New P1/2 trial, Checkpoint inhibition: Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma (clinicaltrials.gov) - Feb 25, 2014
P1/2, N=56, Not yet recruiting, Sponsor: NewLink Genetics Corporation
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Enrollment change, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 038: PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (clinicaltrials.gov) - Feb 24, 2014
P1, N=160, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting N=80 --> 160
- Yervoy (ipilimumab) / Ono Pharma, BMS, NY-ESO-1 TCR / Gilead
New P1 trial, Metastases: Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies (clinicaltrials.gov) - Feb 23, 2014
P1, N=12, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- | Yervoy (ipilimumab) / BMS
New P4 trial, Metastases: Ipi4: A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. (clinicaltrials.gov) - Feb 19, 2014
P4, N=100, Recruiting, Sponsor: Oslo University Hospital
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Metastases: Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) (clinicaltrials.gov) - Feb 18, 2014
P3, N=645, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=80 --> 160 Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / BMS
Enrollment closed, Combination therapy, Metastases: Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma (clinicaltrials.gov) - Feb 13, 2014
P2, N=30, Active, not recruiting, Sponsor: Jewish General Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment change, Combination therapy: Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer (clinicaltrials.gov) - Feb 9, 2014
P1, N=15, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting N=12 --> 15
- ||||| Opdivo (nivolumab) / BMS
New P1/2 trial, MSi-H Biomarker, PD(L)-1 Biomarker: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Feb 9, 2014
P1/2, N=96, Recruiting, Sponsor: Bristol-Myers Squibb
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: CheckMate 143: A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (clinicaltrials.gov) - Feb 9, 2014
P2b, N=260, Recruiting, Sponsor: Bristol-Myers Squibb
N=12 --> 15 Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Combination therapy: Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer (clinicaltrials.gov) - Feb 9, 2014
P1, N=15, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Trial withdrawal, Metastases: Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma (clinicaltrials.gov) - Feb 3, 2014
P2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Yervoy (ipilimumab) / BMS
Enrollment change, Metastases: Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma (clinicaltrials.gov) - Feb 3, 2014
P2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Withdrawn N=33 --> 0
- |||||| New P2b trial, Checkpoint inhibition: NLG-0304: Immunotherapy Study for Patients With Stage IV Melanoma (clinicaltrials.gov) - Feb 2, 2014
P2b, N=100, Recruiting, Sponsor: NewLink Genetics Corporation
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, PD(L)-1 Biomarker: CheckMate 069: Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (clinicaltrials.gov) - Jan 27, 2014
P2, N=150, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=33 --> 0 Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial: Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease (clinicaltrials.gov) - Jan 26, 2014
P2, N=260, Not yet recruiting, Sponsor: European Thoracic Oncology Platform
- |||| Selectikine (EMD 521873) / EMD Serono
Enrollment open, Combination therapy, Metastases: EMR 062235-005: MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma (clinicaltrials.gov) - Jan 21, 2014
P2, N=86, Recruiting, Sponsor: EMD Serono
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Metastases: A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (clinicaltrials.gov) - Jan 15, 2014
P1/2, N=320, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Avastin (bevacizumab) / Roche, Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Abraxane Plus Bevacizumab Versus Ipilimumab as 1st Line Therapy for BRAFwt Metastatic Melanoma (clinicaltrials.gov) - Jan 9, 2014
P2, N=176, Recruiting, Sponsor: Academic and Community Cancer Research United
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Farydak (panobinostat) / Secura Bio, Yervoy (ipilimumab) / BMS
New P1 trial, Combination therapy, Epigenetic controller, Metastases: Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma (clinicaltrials.gov) - Jan 8, 2014
P1, N=36, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD), Yervoy (ipilimumab) / BMS
Enrollment closed: Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma (clinicaltrials.gov) - Jan 5, 2014
P1, N=36, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Jan 2, 2014
P2, N=20, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment change, Metastases: Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine (clinicaltrials.gov) - Dec 30, 2013
P1, N=72, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting N=59 --> 72
- ||||| Firmagon (degarelix) / Astellas, Ferring, Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy (clinicaltrials.gov) - Dec 22, 2013
P2, N=53, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2b trial: CheckMate 143: A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (clinicaltrials.gov) - Dec 19, 2013
P2b, N=260, Recruiting, Sponsor: Bristol-Myers Squibb
- ||| Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (clinicaltrials.gov) - Dec 17, 2013
P2, N=138, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=59 --> 72 Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Dec 16, 2013
P1/2, N=10, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Suspended --> Completed
- Yervoy (ipilimumab) / BMS
Enrollment change, Combination therapy, Surgery, Stroma, Metastases: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (clinicaltrials.gov) - Dec 15, 2013
P1, N=39, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed N=30 --> 39
- | Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (clinicaltrials.gov) - Dec 15, 2013
P2, N=18, Recruiting, Sponsor: Bristol-Myers Squibb
N=30 --> 39 Not yet recruiting --> Recruiting
- Ontak (denileukin diftitox) / Eisai, TSD Japan, Yervoy (ipilimumab) / Ono Pharma, BMS
New P2 trial, Metastases: Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox (clinicaltrials.gov) - Dec 10, 2013
P2, N=42, Recruiting, Sponsor: James Graham Brown Cancer Center
- Yervoy (ipilimumab) / Ono Pharma, BMS
New P1/2 trial, Metastases: A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients (clinicaltrials.gov) - Dec 10, 2013
P1/2, N=42, Recruiting, Sponsor: James Graham Brown Cancer Center
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change: Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (clinicaltrials.gov) - Dec 8, 2013
P1, N=62, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting N=33 --> 62